ShangBay Capital

ShangBay Capital is a venture capital firm established in 2015 and based in Palo Alto, California. The firm specializes in early-stage investments within the medical device, biotechnology, and healthcare technology sectors. With a combined experience of over 100 years, ShangBay Capital's leadership team has cultivated strong relationships with strategic partners and innovators in disruptive technologies. Their investment philosophy focuses on supporting founders who address significant unmet clinical needs with novel solutions, aiming to generate favorable returns by satisfying large market demands.

The firm's expertise lies in understanding global market opportunities, valuation assessment for medical device companies, and building long-term relationships with founders. ShangBay Capital has executed successful deals, helped startups commercialize their products, and expanded their business footprint. The firm has also established a successful record of working with various regulatory agencies to get products approved by the FDA. Leveraging their experience and broad network of operators and clinicians, portfolio companies have been able to accelerate their growth.

Highlights and achievements include being recognized as the #1 most active new device VC from 2020 to 2023, with 13 billion-dollar IPOs and 4 M&As among 9 total exits. Additionally, 11 portfolio companies secured new financing rounds with no down rounds in 2023, and 13 portfolio companies received term sheets and new financing rounds in 2024, with a total capital raised across new financings of approximately $1 billion during 2023-2024. William Dai, the Founding Managing Partner, was named among the Top 25 GrowthCap Healthcare Investors of 2024.